Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro

Journal of Molecular Endocrinology

Volumn 42, Issue 1, 2009, Pages 47-56

  de Bruin, C ^a   Feelders, R A ^a   Waaijers, A M ^a   van Koetsveld, P M ^a   Sprij Mooij, D M ^a   Lamberts, S W J ^a   Hofland, L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; DEXAMETHASONE; DOPAMINE 2 RECEPTOR; GLUCOCORTICOID; MESSENGER RNA; OCTREOTIDE; SOMATOSTATIN RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DOPAMINE; HORMONE ANTAGONIST; ISOPROTEIN; MIFEPRISTONE; SOMATOSTATIN;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CUSHING DISEASE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION REGULATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG SMALL CELL CANCER; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID MEDULLARY CARCINOMA; ANIMAL; CELL LINE; CELL PROLIFERATION; DNA FRAGMENTATION; GENETICS; METABOLISM; RADIOASSAY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE; CELL PROLIFERATION; DEXAMETHASONE; DNA FRAGMENTATION; DOPAMINE; GLUCOCORTICOIDS; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; OCTREOTIDE; PROTEIN ISOFORMS; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SOMATOSTATIN;

EID: 58849099076     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-08-0110     Document Type: Article

References (50)

1. Ambrosi B, Bochicchio D, Fadin C, Colombo P & Faglia G 1990 Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. Journal of Endocrinological Investigation 13 257-261.
2. Barnett P 2003 Somatostatin and somatostatin receptor physiology. Endocrine 20 255-264.
3. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA & Klibanski A 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 91 4482-4488.
4. Boscaro M, Petersenn S, Atkinson AB, Bertherat J, Findling J, Snyder P, McBride K, Reincke M, Ludlam W, Gao B et al. 2006 Pasireotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushing's disease: preliminary safety and efficacy results of a phase II study. Presented at ENDO 2006, p 81. Boston, USA. Abstract OR9-1.
5. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J et al. 2008 Treatment of pituitary dependent Cushing's disease with the multireceptor ligand somato-statin analog pasireotide (Som230): A multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism (In Press).
6. Van Craenenbroeck K, De Bosscher K, Vanden Berghe W, Vanhoenacker P & Haegeman G 2005 Role of glucocorticoids in dopamine-related neuropsychiatric disorders. Molecular and Cellular Endocrinology 245 10-22.
7. Czyrak A, Mackowiak M, Chocyk A, Fijal K & Wedzony K 2003 Role of glucocorticoids in the regulation of dopaminergic neurotransmission. Polish Journal of Pharmacology 55 667-674.
8. Evers BM, Wang X, Zhou Z, Townsend CM Jr, McNeil GP & Dobner PR 1995 Characterization of promoter elements required for cell-specific expression of the neurotensin/neuromedin N gene in a human endocrine cell line. Molecular and Cellular Biology 15 3870-3881.
9. Gaitan D, DeBold CR, Turney MK, Zhou P, Orth DN & Kovacs WJ 1995 Glucocorticoid receptor structure and function in an adrenocorticotropin-secreting small cell lung cancer. Molecular Endocrinology 9 1193-1201.
10. Gordon DF, Woodmansee WW, Lewis SR, James RA, Wood WM & Ridgway EC 1999 Cloning of the mouse somatostatin receptor subtype 5 gene: promoter structure and function. Endocrinology 140 5598-5608.
11. Heaney AP & Melmed S 2004 Molecular targets in pituitary tumours. Nature Reviews. Cancer 4 285-295.
12. de Herder WW & Lamberts SW 1996 Is there a role for somatostatin and its analogs in Cushing's syndrome? Metabolism 45 83-85.
13. de Herder WW, Krenning EP, Malchoff CD, Hofland LJ, Reubi JC, Kwekkeboom DJ, Oei HY, Pols HA, Bruining HA, Nobels FR et al. 1994 Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. American Journal of Medicine 96 305-312.
14. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE et al. 2005 Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. American Journal of Physiology. Endocrinology and Metabolism 289 E278-E287.
15. Hofland LJ, van Koetsveld PM & Lamberts SW 1990 Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995. European Journal of Cancer 26 37-44.
16. Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC & Lamberts SW 1992 Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells. Endocrinology 131 571-577.
17. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ et al. 2004 The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 89 1577-1585.
18. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW et al. 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology 152 645-654.
19. Ikeda K, Lu C, Weir EC, Mangin M & Broadus AE 1989 Transcriptional regulation of the parathyroid hormone-related peptide gene by glucocorticoids and vitamin D in a human C-cell line. Journal of Biological Chemistry 264 15743-15746
20. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA & Nieman LK 2005 Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. Journal of Clinical Endocrinology and Metabolism 90 4955-4962.
21. Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, Jenkins PJ, Monson JP, Grossman AB & Besser GM 2006 The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. Journal of Clinical Endocrinology and Metabolism 91 371-377.
22. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A & Ouafik LH 2000 Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Journal of Clinical Endocrinology and Metabolism 85 781-792.
23. Kelestimur F, Utas C, Ozbakir O, Selcuklu A, Kandemir O & Ozcan N 1996 The effects of octreotide in a patient with Nelson's syndrome. Postgraduate Medical Journal 72 53-54.
24. Kraus J, Woltje M, Schonwetter N & Hollt V 1998 Alternative promoter usage and tissue specific expression of the mouse somatostatin receptor 2 gene. FEBS Letters 428 165-170.
25. Kraus J, Woltje M & Hollt V 1999 Regulation of mouse somatostatin receptor type 2 gene expression by glucocorticoids. FEBS Letters 459 200-204.
26. Lamberts SW, Tilanus HW, Klooswijk AI, Bruining HA, van der Lely AJ & de Jong FH 1988 Successful treatment with SMS 201-995 of Cushing's syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma. Journal of Clinical Endocrinology and Metabolism 67 1080-1083.
27. Lamberts SW, Uitterlinden P & Klijn JM 1989 The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinologica 120 760-766.
28. Lammers CH, D'Souza UM, Qin ZH, Lee SH, Yajima S & Mouradian MM 1999 Regulation of striatal dopamine receptors by corticosterone: an in vivo and in vitro study. Brain Research. Molecular Brain Research 69 281-285.
29. Lee D, Huang W, Copolov DL & Lim AT 1995 Glucocorticoids inhibit D1B, but not D2, receptor-mediated effects on hypothalamic atrial natriuretic factor neurons. Endocrinology 136 5570-5576.
30. Missale C, Nash SR, Robinson SW, Jaber M & Caron MG 1998 Dopamine receptors: from structure to function. Physiological Reviews 78 189-225.
31. Park S, Kamegai J & Kineman RD 2003 Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects. Neuroendocrinology 78 163-175.
32. Patel YC 1999 Somatostatin and its receptor family. Frontiers in Neuroendocrinology 20 157-198.
33. Petersenn S, Rasch AC, Presch S, Beil FU & Schulte HM 1999 Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Molecular and Cellular Endocrinology 157 75-85.
34. Petersenn S, Rasch AC, Bohnke C & Schulte HM 2002 Identification of an upstream pituitary-active promoter of human somatostatin receptor subtype 5. Endocrinology 143 2626-2634.
35. Petrini L, Gasperi M, Pilosu R, Marcello A & Martino E 1994 Longterm treatment of Nelson's syndrome by octreotide: a case report. Journal of Endocrinological Investigation 17 135-139.
36. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29 e45.
37. Phlipponneau M, Nocaudie M, Epelbaum J, De Keyzer Y, Lalau JD, Marchandise X & Bertagna X 1994 Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropinsecreting bronchial carcinoid tumor. Journal of Clinical Endocrinology and Metabolism 78 20-24.
38. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ et al. 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 89 2452-2462.
39. Pivonello R, Ferone D, de Herder WW, Faggiano A, Bodei L, de Krijger RR, Lombardi G, Colao A, Lamberts SW & Hofland LJ 2007 Dopamine receptor expression and function in corticotroph ectopic tumors. Journal of Clinical Endocrinology and Metabolism 92 65-69.
40. Pivonello R, De Martino MC, Cappabianca P, de Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW & Colao A 2008 The medical treatment of Cushing's disease effectiveness of chronic treatment with the dopamine agoinst cabergoline in patients unsuccessfully treated by surgery. Journal of Clinical Endrocrinology and Metabolism (In Press).
41. Rasmussen R 2001 Quantification on the LightCycler. In apid Cycle Real-Time PCR, Methods and Applications, pp 21-34. Eds S Meuer, C Wittwer & S Nagakawara. Heidelberg: Springer Press.
42. Ray DW, Littlewood AC, Clark AJ, Davis JR & White A 1994 Human small cell lung cancer cell lines expressing the proopiomelanocortin gene have aberrant glucocorticoid receptor function. Journal of Clinical Investigation 93 1625-1630.
43. Sigala S, Missale C, Tognazzi N & Spano P 2000 Differential gene expression of dopamine D-2 receptor subtypes in rat chromaffin cells and sympathetic neurons in culture. Neuroreport 11 2467-2471.
44. Smit P, Russcher H, de Jong FH, Brinkmann AO, Lamberts SW & Koper JW 2005 Differential regulation of synthetic glucocorticoids on gene expression levels of glucocorticoid-induced leucine zipper and interleukin-2. Journal of Clinical Endocrinology and Metabolism 90 2994-3000.
45. Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J & Muller OA 1994 Octreotide exerts different effects in vivo and in vitro in Cushing's disease. European Journal of Endocrinology 130 125-131.
46. Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP et al. 2007 Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. European Journal of Endocrinology 156 65-74.
47. Tsagarakis S, Christoforaki M, Giannopoulou H, Rondogianni F, Housianakou I,Malagari C, Rontogianni D, Bellenis I & Thalassinos N 2003 A reappraisal of the utility of somatostatin receptor scintigraphy in patients with ectopic adrenocorticotropin Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 88 4754-4758.
48. Uwaifo GI, Koch CA, Hirshberg B, Chen CC, Hartzband P, Nieman LK & Pacak K 2003 Is there a therapeutic role for octreotide in patients with ectopic Cushing's syndrome? Journal of Endocrinological Investigation 26 710-717.
49. von Werder K, Muller OA & Stalla GK 1996 Somatostatin analogs in ectopic corticotropin production. Metabolism 45 129-131.
50. Xu Y, Berelowitz M & Bruno JF 1995 Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells. Endocrinology 136 5070-5075.